Expression of SIRT2 and SIRT6 in retinoblastoma

Ophthalmic Research

Volumn 53, Issue 2, 2015, Pages 100-108

  Orellana, Maria Eugenia ^a   Quezada, Carlos ^b   Maloney, Shawn C ^b   Antecka, Emilia ^b   Balazsi, Matthew ^b   Burnier, Miguel N ^b  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Retinoblastoma; SIRT2; SIRT6

Indexed keywords

MONOCLONAL ANTIBODY; SIRTUIN 2; SIRTUIN 6; SIRT2 PROTEIN, HUMAN; SIRT6 PROTEIN, HUMAN; SIRTUIN;

ARTICLE; CHILD; CONTROLLED STUDY; CORNEA EPITHELIUM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA GANGLION CELL; RETINOBLASTOMA; ENUCLEATION; ENZYME IMMUNOASSAY; EYE ENUCLEATION; FEMALE; INFANT; MALE; METABOLISM; PATHOLOGY; RETINAL NEOPLASMS;

CHILD; CHILD, PRESCHOOL; EYE ENUCLEATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MALE; RETINAL NEOPLASMS; RETINOBLASTOMA; SIRTUIN 2; SIRTUINS;

EID: 84923076498     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000368718     Document Type: Article

References (37)

1. Kivela T: The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93: 1129-1131.
2. Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HSL, et al: Retinoblastoma. Lancet 2012; 379: 1436-1446.
3. MacCarthy A, Bayne AM, Brownbill PA, Bunch KJ, Diggens NL, Draper GJ, et al: Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer 2013; 108: 2455-2463.
4. Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68: 820-823.
5. Comings DE: A general theory of carcinogenesis. Proc Natl Acad Sci U S A 1973; 70: 3324-3328.
6. Dhar SU, Chintagumpala M, Noll C, Chevez-Barrios P, Paysse EA, Plon SE: Outcomes of integrating genetics in management of patients with retinoblastoma. Arch Ophthalmol 2011; 129: 1428-1434.
7. Ray A, Gombos DS, Vats TS: Retinoblastoma: an overview. Indian J Pediatr 2012; 79: 916-921.
8. Poulaki V, Mukai S: Retinoblastoma: genetics and pathology. Int Ophthalmol Clin 2009; 49: 155-164.
9. Chintagumpala M, Chevez-Barrios P, Paysse EA, Plon SE, Hurwitz R: Retinoblastoma: review of current management. Oncologist 2007; 12: 1237-1246.
10. Liu Q, Wang Y, Wang H, Liu Y, Liu T, Kunda PE: Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol 2013; 139: 1357-1372.
11. Carafa V, Nebbioso A, Altucci L: Sirtuins and disease: the road ahead. Front Pharmacol 2012; 3: 4.
12. Morris BJ: Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med 2013; 56: 133-171.
13. Donmez G, Outeiro TF: SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 2013; 5: 344-352.
14. Roth M, Chen WY: Sorting out functions of sirtuins in cancer. Oncogene. Nature Publishing Group 2014; 33: 1609-1620.
15. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E: The human Sir2 ortholog, SIRT2, is an NAD+ dependent tubulin deacetylase. Mol Cell 2003; 11: 437-444.
16. Dryden SC, Nahhas FA, Nowak JE, Goustin A, Tainsky MA: Role for human SIRT2 NADdependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol 2003; 23: 3173-3185.
17. Finnin MS, Donigian JR, Pavletich NP: Structure of the histone deacetylase SIRT2. Nat Struct Biol 2001; 8: 621-625.
18. Inoue T, Hiratsuka M, Osaki M, Oshimura M: The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007; 6: 1011-1018.
19. Harting K, Knoll B: SIRT2-mediated protein deacetylation: an emerging key regulator in brain physiology and pathology. Eur J Cell Biol 2010; 89: 262-269.
20. Kim H-S, Vassilopoulos A, Wang R-H, Lahusen T, Xiao Z, Xu X, et al: SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011; 20: 487-499.
21. Hou H, Chen W, Zhao L, Zuo Q, Zhang G, Zhang X, et al: Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ. J Clin Pathol 2012; 65: 1088-1096.
22. Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, et al: Proteomicsbased identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003; 309: 558-566.
23. He X, Nie H, Hong Y, Sheng C, Xia W, Ying W: SIRT2 activity is required for the survival of C6 glioma cells. Biochem Biophys Res Commun 2012; 417: 468-472.
24. Dan L, Klimenkova O, Klimiankou M, Klusman J-H, van den Heuvel-Eibrink MM, Reinhardt D, et al: The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 2012; 97: 551-559.
25. Villalba JM, Alcain FJ: Sirtuin activators and inhibitors. Biofactors 2012; 38: 349-359.
26. Olmos Y, Brosens JJ, Lam EW-F: Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist Updat 2011; 14: 35-44.
27. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al: Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124: 315-329.
28. Michishita E, McCord RA, Berber E, Kioi M, Padilla-Nash H, Damian M, et al: SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 2008; 452: 492-496.
29. Van Meter M, Mao Z, Gorbunova V, Seluanov A: SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 2011; 10: 3153-3158.
30. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I: Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 2008; 55: 2016-2027.
31. Anders M, Fehlker M, Wang Q, Wissmann C, Pilarsky C, Kemmner W, et al: Microarray meta-analysis defines global angiogenesis-related gene expression signatures in human carcinomas. Mol Carcinog 2013; 52: 29-38.
32. Sebastian C, Zwaans BMM, Silberman DM, Gymrek M, Goren A, Zhong L, et al: The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012; 151: 1185-1199.
33. Khelfaoui F, Validire P, Auperin A, Quintana E, Michon J, Pacquement H, et al: Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer 1996; 77: 1206-1213.
34. Chantada G, Doz F, Antoneli CBG, Grundy R, Clare Stannard FF, Dunkel IJ, et al: A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006; 47: 801-805.
35. Lai C-C, Lin P-M, Lin S-F, Hsu C-H, Lin H-C, Hu M-L, et al: Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol 2013; 34: 1847-1854.
36. Ouaissi M, Sielezneff I, Silvestre R, Sastre B, Bernard J-P, Lafontaine JS, et al: High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 2008; 15: 2318-2328.
37. Ma W, Stafford LJ, Li D, Luo J, Li X, Ning G, et al: GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. J Cell Biochem 2007; 100: 1376-1386.